Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between
Background
Monitoring trends in residual risk of transfusion-transmitted viral infections is important to assess improvements in blood safety and to adapt the reduction risk policies.
These trends were analysed over 10 overlapping periods of 3 years from 1992 to 2003.
The 2001-03 estimates were compared to the results of HIV-1 and HCV NAT implemented on all blood donations in July 2001.
Method
As the major source of risk is associated with the window period, a seroconversion incidence model was used to estimate residual risks:
Residual risk = Incidence rate x Window period duration.
Incidence rate is the number of donors who underwent seroconversion during a 3-year period divided by the number of person-years calculated by summing time intervals between the first and the last donation of each donor during the study period. If the previous seronegative donation was not transfusable due to a positive result for another marker (elevated ALT, anti-HBc,...), the incident case was excluded from the analysis. Because of the transient presence of HBsAg, an adjustment was made to estimate the incidence rate for HBV.
For each virus, the length of the window period was derived from published data: 22 days for anti-HIV Ab, 66 days for anti-HCV Ab and 56 days for HBsAg. With the use of minipool NAT, window periods were estimated at 12 days for HIV and 10 days for HCV.
For the first 7 periods, Incidence rates were calculated from data collected by the blood centers belonging to the Transfusion-Transmissible Agents Working Group which collect more than 50% of blood donations in France, and for the 3 last periods, on the overall blood supply.
Chi-square for linear trends was used for trends analysis.
Results

I. Incidence rates
The incidence rates of HIV, HBV and HCV seropositivity decreased significantly over time (table 1) . The most important decrease was for HCV: incidence rate on the last period was 7 times lower compared with the first one. For HBV, incidence rate on the last period was near 6 times lower compared with the first one. For HIV, the decrease was important until the 1995-97 period but was weaker afterwards.
Since the 1998-2000 period, HIV incidence rates are higher than HCV incidence rates. 
Conclusion
Given the improvements in donor recruitment and selection, the continuous progress in screening assays and the preventive measures taken in the community to control infections, the current residual risk of transfusion-transmitted viral infections is very low. Without NAT, the overall residual risk for the 3 viruses combined (HIV, HCV, HBV) decreased from 1 in 65,000 to 1 in 350,000 donations between 1992 and 2003. Since the implementation of NAT, the current overall residual risk is 1 in 500,000 donations (30% less than without NAT). 
